[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638671":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":56,"collaborators":60,"id":64,"slug":25,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":65,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":25,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Tri-Service General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tirzepatide arm","ACTIVE_COMPARATOR","starting at 2.5 mg weekly and escalated every month (5.0 mg, 7.5 mg to 10 mg) as tolerated",[13],"Drug: Tirzepatide with lifestyle modification",{"label":15,"type":10,"description":16,"interventionNames":17},"Semaglutide arm","starting at 0.25 mg weekly and escalated every month (0.5 mg, 1.0 mg, 1.7 mg to 2.4 mg) as tolerated",[18],"Drug: Semaglutide with lifestyle modification",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tirzepatide with lifestyle modification","Starting at Tirzepatide 2.5 mg weekly and escalated as tolerated to 10 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Semaglutide with lifestyle modification","Starting at Semaglutide 0.25 mg weekly and escalated as tolerated to 2.4 mg along with standardized lifestyle counseling by a dietitian (caloric deficit, physical activity guidance) and written materials.",[15],[31],{"name":32,"affiliation":33,"role":34},"Feng-Chih Kuo, M.D., Ph.D.","Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan.","STUDY_DIRECTOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","886-2-87923311","12687","shoummie@hotmail.com",[42],{"facility":5,"status":43,"city":44,"state":25,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Taipei","114202","Taiwan","TW",{"type":49,"coordinates":50},"Point",[51,52],121.52639,25.05306,{"lat":52,"lon":51},[55],{"name":32,"role":37,"phone":38,"phoneExt":39,"email":40},{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Feng-Chih Kuo","Director, Head of the Division of Endocrinology and Metabolism, Principal Investigator, Associate Professor",[61],{"name":62,"class":63},"National Science and Technology Council, Taiwan","OTHER_GOV","100638671",false,"NCT07589322","Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs","Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study","COMPARE-AT","Inclusion Criteria:\n\n* Age 20-65 years.\n* BMI ≥27 kg\u002Fm² with metabolic syndrome (ATP III or IDF criteria).\n* Stable background medications (antihypertensives, statins, etc.) for ≥3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* History of diabetes; history of pancreatitis; personal\u002Ffamily history of medullary thyroid carcinoma or MEN2.\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m², decompensated liver disease, NYHA class III-IV heart failure.\n* Recent (\\\u003C3 months) acute coronary syndrome, stroke, or coronary revascularization.\n* Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months.\n* Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).","ALL","20 Years","65 Years",{"count":75,"type":76},120,"ESTIMATED","INTERVENTIONAL",[79],"NA","This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.",[82],"Obesity and Metabolic Syndrome",[84,85,86,87,88],"tirzepatide","semaglutide","obesity","metabolic syndrome","multi omic","2026-05-10",{"date":91,"type":92},"2026-05-15","ACTUAL",{"date":94,"type":92},"2026-03-31",{"date":96,"type":76},"2029-09-30",{"name":5,"class":6},1]